Somite AI, a Boston, MA-based TechBio company leveraging foundation models and proprietary AI to accelerate human cell therapy development, raised an undisclosed amount in Series A funding.
The round was led by Khosla Ventures, with participation from SciFi VC, the Chan Zuckerberg Initiative, Fusion Fund, Ajinomoto Group Ventures, Pitango HealthTech, TechAviv, Harpoon Ventures, along with angel investors such as Dr. R. Martin Chavez (former Chairman of Recursion), and Fidji Simo (outgoing CEO of Instacart and incoming CEO of Applications at OpenAI).
The company intends to use the funds to accelerate key therapeutic programs, including beta cells for type 1 diabetes, articular cartilage for orthopedic applications, satellite cells for muscular diseases, and hematopoietic cells for blood disorders, and further develop the capabilities of its DeltaStem platform.
Founded by Dr. Micha Breakstone and Dr. Jonathan Rosenfeld, Somite AI is building DeltaStem, a platform and foundation model designed to improve the production of human cells. Its proprietary capsule technology generates cell state transition data that feeds into the DeltaStem foundation model, accelerating and optimizing the development of novel cell differentiation protocols.
The team includes:
- Prof. Olivier Pourquié, member of the National Academies of Science and Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Prof. Allon Klein, James Prize recipient, Harvard Medical School
- Prof. Jay Shendure, member of the National Academy of Sciences, University of Washington
- Prof. Cliff Tabin, Chair of Genetics at Harvard Medical School, member of the National Academy of Sciences
FinSMEs
13/05/2025